CHINESE PHARMACEUTICAL MARKET: FORECASTS AND OUTLOOKS 2014-2024

中国の製薬市場予測と展望(2014-2024)

◆タイトル:CHINESE PHARMACEUTICAL MARKET: FORECASTS AND OUTLOOKS 2014-2024
◆商品コード:VISG409046
◆調査・発行会社:visiongain
◆発行日:2014年7月
◆ページ数:305
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"中国の製薬市場予測と展望(2014-2024)"について調査・分析し、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、専門家の見解、結論などの情報をお届けいたします。

Medical revenues in China – your guide to trends, companies and potentials
What’s the outlook for the Chinese pharma market? Can it sustain high growth? Visiongain’s updated report gives you forecasted revenues there to 2024. That work explains medical and technological trends, prospects and commercial opportunities.

China still holds great potential for medicines and their sales. Our study gives data and predictions for that industry and market. You investigate activities of domestic and international companies – pharma and contract – and assess their environment.

That new analysis shows the most lucrative parts of Chinese healthcare. Read on to explore that market and see what its future could be worth to pharma industries.

Forecasts and other analyses to help you stay ahead for Chinese medical business
Our report gives you revenue predictions to 2024, historical data, growth rates and market shares. It lets you discover business outlooks, including research and development (R&D). You also gain 87 tables, 117 charts and four interviews.

Is finding data on Chinese healthcare proving difficult? Now you can stay ahead in knowledge, benefiting your research, analyses and decisions. The following sections explain.

Sales predictions for the Chinese drug market and its segments – discover potentials
Along with revenue prediction for the overall Chinese pharma market, you see individual forecasting to 2024 for these main submarkets:
• Hospitals
• Retail pharmacies
• Sales via other channels, including over-the-counter (OTC) products
• Small-molecule pharmaceuticals – with sub forecasts for novel and generic drugs
• Biological drugs – with sub forecasts for novel and biosimilar biologics, and for vaccines
• Traditional Chinese medicines (TCM).

Our study also gives individual revenue forecasts to 2024 for sales by therapeutic area:
• Infectious diseases – with sub-forecasts for antibacterial drugs (antibacterials), vaccines and antiviral agents (antivirals)
• Cancer – applications in oncology, anticancer agents
• Cardiovascular disorders – with sub-forecasts for hypertension and dyslipidaemia therapies
• Diabetes
• Respiratory diseases – with sub-forecasts for COPD and asthma treatments
• Autoimmune and inflammatory conditions
• Central nervous system (CNS) disorders – with sub-forecasts for antidepressants and antipsychotics
• Other medical needs (grouped).

Forecasts for contract research (CROs), manufacturing (CMOs) and sales (CSOs)
You also gain individual revenue forecasting to 2024 for these related industries in China:
• Contract medical sales
• Contract research – with sub forecasts for drug discovery and clinical trials outsourcing
• Contract manufacturing and other Chinese pharma production output – with division into drug formulations, active pharmaceutical ingredients (APIs), medical devices, TCM agents, and biologicals.

Also do you understand the changing market – expanding and widening needs? There our report helps you identify potential and find opportunities for revenue growth.

Epidemiological trends – find what patient needs underpin Chinese healthcare
Also for prominent diseases in China discover prevalence and incidences to 2025.
And get our patient flow models for diseases, seeing numbers of patients diagnosed, and treated cases predicted to 2024.

Also explore how companies serve those treatment needs:
• Number of clinical trials registered in China by phase
• Investigational new drug applications by therapy area
• Contract research organisations and their activities
• Chinese companies with innovative pharmaceutical developments
• Biotechnology there, including biomarker testing, regenerative medicine and stem cell research.

You also explore what influences Chinese healthcare industries and markets.

Characteristics, forces and issues affecting the Chinese pharma industry and market
Our report discusses issues, regulations and events affecting Chinese healthcare and related industries from 2014:
• Epidemiological trends, including effects of industrialisation and ageing population
• Sales outlets, distribution channels and product classes most important from 2014
• Manufacturing and R&D, including biotechnology and trends for venture capital
• Healthy China 2020 and other investments and reforms
• Healthcare funding – driving and restraining forces
• Opportunities in treating chronic diseases, including challenges of HIV and hepatitis.

That work also discusses other aspects of medical services and businesses in China, including these developments:
• The Anhui model
• Investment in rural healthcare – high demands needing served
• Growth of contract sales activities and other pharma outsourcing (inc. off-shoring)
• Branded generics – their prospects
• Biosimilar manufacturers – outlooks, including developing bio-betters.

That way you explore technological, economic, social and political trends. You also analyse that market’s strengths, weaknesses, opportunities and threats for businesses. Discover what the future holds.

Leading drugs companies – domestic and foreign – and 2014 market value
What happens next? Our report predicts overall pharma sales in China will reach $97.4bn in 2014, expanding onwards to 2024. See what’s possible.

The study covers these multinationals and others, with discussion of the top 10 big pharma companies operating in China:
• Bayer
• Pfizer
• AstraZeneca
• Roche
• Merck and Co.

Our work also discusses these domestic companies, and other top 30 firms based there:
• Yangtze Pharma
• Harbin Pharmaceutical
• Guangzhou Baiyunshan Pharmaceutical
• Kangmei Pharmaceutical
• Yunnan Baiyao.

In our study you find 320 organisations mentioned. Also you read our interviews with other authorities on Chinese pharma – you see opinions and discussions.

Prospects for product and service sales in China are strong, and from 2014 there will arise many opportunities for companies. Our work shows you the technological, medical and commercial possibilities, helping you succeed. Find that top emerging country’s potential.

【レポートの目次】

1. Report Summary
1.1 The Chinese Pharmaceutical Market Review
1.2 The Chinese Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How this Report Delivers
1.5 Main Questions Answered by This Report
1.6 Who is this Report For?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Overview of the Chinese Pharmaceutical Market
2.1 Chinese Pharmaceutical Market in 2013
2.2 China in the Global Pharmaceutical Market, 2013
2.3 Chinese Pharmaceutical Market, 2014-2024
2.4 Overview of Sales Channels in the Chinese Market in 2013
2.5 Leading Disease Areas in the Chinese Market in 2013
2.6 Overview of Pharmaceutical Manufacturing China, 2013
2.7 Overview of Outsourced Pharmaceutical Research & Development China, 2013
2.8 The Top 30 Domestic Chinese Companies: A Fragmented Market
2.9 Multinational Companies and Their Chinese Strategies
2.10 Crucial Chinese State Bodies
2.11 High Growth in Spite of Low Healthcare Spending as a Proportion of GDP
2.12 Price Inflation and Out-of-Pocket Payments
2.13 Picking up the Tab
2.14 Healthy China 2020: ‘Unprecedented in Human History’
2.15 Achievements and Potential of the Healthy China 2020 Initiative
2.16 Expanding the EDL
2.17 ‘The Black Hole for Healthcare Funding’
2.18 Paying for Chronic Diseases
2.19 The Anhui Model: The Unlikely Shape of Things to Come?
2.20 Compulsory Licences: Ominous or Insignificant Development?

3. Epidemiology of Disease in China, 2014-2024
3.1 Disease Prevalence in China, 2014-2024
3.2 Incidence of Diseases in China, 2014-2024
3.3 Disease Mortality in China, 2014-2024
3.3.1 Cardiovascular Diseases: Leading Cause of Mortality in 2012
3.3.2 Stroke: China’s Number One Killer, 2012
3.3.3 Forecast Chinese Broad Cause Mortality: The Rising Toll of Cancer
3.3.4 Forecast Specific Causes of Death in China: Lung Cancer Critical Threat to Health

4. Sales Channels in the Chinese Pharmaceutical Market, 2014-2024
4.1 Hospital Sales are the Dominant Channel
4.2 Distribution Channels are Fragmented and Dispersed Compared to Western Counterparts
4.2.1 Issues with China’s Pharmaceutical Distribution Model
4.2.2 Problems with Fragmented Distribution Networks
4.2.3 Consolidation Within the Distribution Network is Underway
4.3 Sales Channel Forecast, 2014-2024
4.4 Hospital Sales, 2014-2024
4.4.1 Hospitals: Foundation of the Chinese Healthcare System
4.4.2 Chinese Hospitals in the Era of Reform
4.5 Retail Pharmacies, 2014-2024
4.5.1 Difficulties in Retail Pharmacy Market Estimates
4.5.2 Prospects for the Retail Pharmacy Sales Channel Driven Through Over the Counter (OTC) Sales, 2014-2024
4.5.3 Domestic Chinese OTC Drug Manufacturers, 2013
4.6 Other Sales Channels, 2014-2024
4.6.1 Other Sales Channels – The “Grey” Pharmaceutical in China
4.6.2 Rural Healthcare Investment
4.7 The World’s Largest Sales Force
4.7.1 Chinese Contract Sales Market Forecast, 2014-2024
4.7.2 Concerns over Bribery in Chinese Pharmaceutical Sales, 2013

5. Leading Product Classes in the Chinese Market, 2014-2024
5.1 Conventional Pharmaceuticals Are the Critical Component of the Market, 2013
5.2 Product Classes in the Chinese Market: Market Projections 2014-2018
5.3 Product Classes in the Chinese Market: Market Projections 2018-2024
5.4 Small Molecules: Crucial Components of the Chinese Pharmaceutical Market Through to 2024
5.4.1 Generics to Remain the Foundation of the Market, 2014-2024
5.4.2 Market Structure Favours Generics
5.4.3 Health Reforms Increase Opportunities for Branded and Generic Drugs
5.4.4 Branded Generics: A Way Forward in China?
5.4.5 AstraZeneca and Pfizer Leading in Branded Generics
5.4.6 Drivers and Restraints in the Small Molecules Pharmaceuticals Segment, 2014
5.5 Traditional Chinese Medicine, 2014-2024
5.5.1 TCM: A Unique Phenomenon
5.5.2 TCM Use is Ubiquitous Across China
5.5.3 Governmental Promotion of TCM
5.5.4 Expansion of TCM
5.5.5 Players in the TCM Field
5.5.6 Drivers and Restraints in the TCM Field, 2014
5.6 Chinese Biological Drug Market, 2014-2024
5.6.1 Vaccines: A Major Class of Biological Product in China
5.6.2 Roche Finding a Way Forward with Branded Biologics
5.6.3 China Leads the Way on Biosimilars
5.6.4 Chinese Biosimilar Development Guidelines Set for Release
5.6.5 Biosimilars Account for Less than Half of Biotech Revenues in China
5.6.6 Biosimilar Insulin Uptake in China 2014
5.6.7 Bio-Betters Made in China
5.6.8 Overview of Chinese Biosimilar Manufacturers
5.6.9 Drivers and Restraints in the Biologics Segment, 2014

6. Leading Therapeutic Areas, 2014-2024
6.1 China’s Shifting Disease Burden
6.2 Forecasted Disease Areas in the Chinese Market, 2014-2024
6.3 The Rise of Diabetes and Restriction on Antibacterial Drug Spending: Market Share by Disease, 2014-2024
6.4 Infectious Diseases Segment, 2014-2024
6.4.1 Infectious Diseases Market Forecast, 2014-2024
6.4.2 Antibiotics: China’s Main Medicine
6.4.3 Cephalosporins: China’s Antibiotic of Choice
6.4.4 Antibiotics Stewardship in China: Fighting Against the Tide
6.4.5 Developing Antibacterials in China for China
6.4.6 Vaccine Market Forecast, 2014-2024
6.4.7 Vaccinating Hepatitis B in China
6.4.8 Fragmented Vaccines Sector
6.4.9 Multinational Vaccine Manufacturers Cutting Their Share
6.4.10 Treating China’s HIV and Hepatitis Cases
6.4.11 Drivers and Restraints for the Infectious Diseases Market, 2014
6.5 Cardiovascular Segment 2014-2024
6.5.1 Cardiovascular Disease Market Forecast, 2014-2024
6.5.2 Modelling the Chinese Hypertension Market, 2014-2024
6.5.3 Forecast Hypertension Market in China, 2014-2024
6.5.4 Leading Products Classes in Hypertension Market, 2013
6.5.5 Multinationals Dominate the Chinese Hypertension Market, 2013
6.5.6 Modelling the Chinese Dyslipidaemia Market, 2014-2024
6.5.7 Forecast Dyslipidaemia Market in China, 2014-2024
6.5.8 Cardiovascular Disease is a Major Focus for Western Companies
6.5.9 TCM Also Heavily Focused on Cardiovascular Treatments
6.5.10 Domestic Companies in the Cardiovascular Segment
6.5.11 Drivers and Restraints in the Cardiovascular Segment, 2014
6.6 Anticancer Drug Market 2014-2024
6.6.1 Anticancer Drug Market Forecast, 2014-2024
6.6.2 Cancer: The Price for China’s Rapid Modernisation?
6.6.3 Incidence of Cancer in China, 2014-2024
6.6.4 Targeted Therapeutics Making Headway in Market
6.6.5 Cost of Treatment Drives Anticancer Drug Choice in China
6.6.6 Tailoring Cancer Treatments for China
6.6.7 Biomarker Testing in China
6.6.8 Domestic Participants in the Anticancer Drugs Market
6.6.9 Drivers and Restraints in the Oncology Segment, 2014
6.7 China: The Diabetes Centre of the World, 2014-2024
6.7.1 Modelling the Chinese Diabetes Treatment Market, 2014-2024
6.7.2 The Largest Diabetes Drugs Market in the World: Forecast 2014-2024
6.7.3 Diabetes in a Form Characteristic of China
6.7.4 Diabetes Management in China
6.7.5 Novo Nordisk, Sanofi and Lilly: The Diabetes Big Three Compete for the Chinese Market
6.7.6 Other Companies Aiming for the Diabetes Segment
6.7.7 Drivers and Restraints in the Diabetes Segment, 2014
6.8 Central Nervous System (CNS) Diseases Market 2014-2024
6.8.1 Forecast CNS Disease Market, 2014-2024
6.8.2 Modelling the Chinese Depression Drugs Market, 2014-2024
6.8.3 Forecast Depression Treatments Market in China, 2014-2024
6.8.4 Antidepressants Market by Product Class, 2013
6.8.5 Modelling the Schizophrenia Drugs Market in China, 2014-2024
6.8.6 Forecast Antipsychotic Drugs Market in China, 2014-2024
6.8.7 Leading Antipsychotic Drugs in the Chinese Market, 2013
6.8.8 The Ageing Population of China Will Drive Growth for CNS Drug Sales
6.8.9 Neurodegenerative Diseases and Dementia Set to Rise
6.8.10 Pain Relief a New Priority for China
6.8.11 Drivers and Restraints in the CNS Diseases Segment, 2014
6.9 Respiratory Diseases Segment, 2014
6.9.1 Respiratory Drugs Market Forecast, 2014-2024
6.9.2 Modelling the COPD Market in China, 2014-2024
6.9.3 COPD Market Forecast, 2014-2024
6.9.4 Modelling the Chinese Asthma Treatment Market, 2014-2024
6.9.5 Asthma Medical Market Forecast, 2014-2024
6.9.6 Leading Respiratory Drug Classes, 2013
6.9.7 AstraZeneca Leading Respiratory Diseases Research
6.9.8 Drivers and Restraints in the Respiratory Diseases Segment, 2014
6.10 Autoimmune/Inflammatory Diseases Segment, 2014
6.10.1 Autoimmune and Inflammatory Diseases Market Forecast, 2014-2024
6.10.2 Diagnosis is Crucial and Biological Drugs are Often Used
6.10.3 TCM Use is Widespread, as are Biosimilars
6.10.4 Drivers and Restraints for Autoimmune and Inflammatory Diseases Segment, 2014
6.11 Other Disease Areas

7. Chinese Pharmaceutical Manufacturing, 2014-2024
7.1 ‘Workshop of the World’: China as Pharmaceutical Manufacturing Hub
7.2 Chinese Contract Manufacturing Since the 1990s
7.3 The Burgeoning Contract Manufacturing Market in China, 2014-2024
7.4 Outsourcing to Emerging National Markets from Developed Markets
7.4.1 Demand for Contracted Services in China
7.4.2 Domestic Demand for Pharmaceutical Contract Manufacturing Services
7.5 Manufacturing Partnerships for Multinationals and Small Domestic Companies
7.6 Improved Manufacturing Regulations in China
7.6.1 New Regulations for Excipients and Guidance for API Manufacturing 2012-2013
7.6.2 What Are the Consequences of Stricter Manufacturing Regulations in China?
7.7 Chinese CMOs Are Investing in Bio-pharmaceutical Manufacturing
7.8 Drivers and Restraints for Chinese CMOs, 2013
7.9 China’s Manufacturing Output, 2011-2013
7.9.1 Chinese Pharmaceutical Manufacturing Output to Treble in Value by 2024
7.9.2 TCM and Related Herbal Drugs: The Leading Area of ‘Pharmaceutical’ Output by 2024
7.9.2.1 The 12th Five-Year Plan Favours the TCM Industry
7.9.3 Pharmaceutical Formulations: Chinese Output to 2024
7.9.4 APIs: China to Retain its Dominance of Global Export Markets
7.9.4.1 Tighter Regulation to Bring China’s API Standards in Line with International Norms
7.9.5 Biologics Manufacturing: the Fastest-Growing Area of Chinese Pharmaceutical Industry Output to 2024
7.9.5.1 China Targeting Biomanufacturing Leadership
7.9.6 Medical Devices Output to 2024
7.9.7 Chinese Medical Device Manufacturers Continuing to Ascend the Value Chain
7.10 Chinese Manufacturing: Conclusions

8. Chinese Pharmaceutical R&D, 2014-2024
8.1 China: Research Hub for Asia Pacific and Beyond
8.2 China’s Contract Research Outsourcing Market
8.2.1 Double Digit Growth in the Chinese Contract Research Outsourcing Market, 2014-2024
8.3 Clinical Trials are the Heart of the Chinese CRO Market
8.3.1 Over 2,000 Active Clinical Trials in China in 2013
8.3.2 Chinese Government Intervention and Promotion of Clinical Trials Research
8.3.3 New Guidelines for Phase I Trials
8.3.4 Improving China’s Clinical Trial Data Management
8.3.5 Increased Outsourcing of Preclinical Research to China
8.3.6 China and India are Crucial to Growth in Drug Discovery Outsourcing
8.3.7 Multinational Contract Research Organisations in China
8.4 Major Domestic Chinese Contract Research Organisations
8.4.1 Drivers and Restraints for Contract Research Outsourcing in China, 2014
8.4.2 Innovation in the Domestic Chinese Pharmaceutical Industry
8.4.3 Domestic Drug Discovery in China
8.4.4 China Still Lacks First-Class Laboratory Facilities
8.4.5 Innovative Biotechnology in China
8.4.6 China Has the World’s Largest and Most Affordable Genomic Sequencing Facilities
8.4.7 Critical Mass in China for Biomarker Testing Breakthroughs
8.4.8 Chinese Regenerative Medicine
8.4.9 Stem Cell Research in China
8.4.10 Stem Cell Controversies
8.5 Chinese Pharmaceutical Research: Conclusions

9. Qualitative Analysis of the Chinese Pharmaceutical Market 2014-2024
9.1 Strengths: China Has Major Healthcare Challenges and is Paying to Improve its Treatment System
9.2 Domestic Disease Burden Growing With GDP
9.3 The Market to Date is Underdeveloped
9.4 The Government’s Investment in Healthcare
9.5 Progressive Urbanisation Continues to Drive Healthcare Spending
9.6 Weaknesses: China is Fundamentally Different from Other Pharmaceutical Markets
9.7 Chinese Healthcare has Deep Systemic Challenges
9.8 China’s Domestic Solutions to Medical Need
9.9 Fears over Bribery and Corruption in the Chinese Pharmaceutical Market
9.10 IP Remains an Issue, 12 Years After China Joined the WTO
9.11 Opportunities: The Scramble for China
9.12 Diversifying Portfolios for China
9.13 Tailoring Portfolios for the Market
9.14 Building Closer Links with the Domestic Chinese Pharmaceutical Industry
9.15 Threats: A House Built on Sand?
9.16 Making a Profit Under the Anhui Model
9.17 Growth Via the State: Will this Work Longer Term?
9.18 How Long will Outsourcing be Worthwhile?
9.19 Social Factors: Who are the Chinese People, and What Do They Want from the Pharmaceutical Industry?
9.20 The Ageing Dragon
9.21 The Obesity Epidemic
9.22 The Effect of Social Factors on Medical Treatment in China
9.23 Technological Factors: Will China Domesticate Healthcare Technologies?
9.24 Economic Factors: Can the Chinese Miracle Continue, and What Happens to Healthcare if it Doesn’t?
9.25 China’s Rise as an Economic Superpower
9.26 What are the Underlying Problems?
9.27 The Five-Year Plan – What Happens Next?
9.28 Political: What Will the Chinese Government Do?

10. Research Interviews
10.1 Interview with Dr. Greg Scott, Founder, ChinaBio Group
10.1.1 Future Prospects for the Chinese Pharmaceutical Market
10.1.2 Cancer is at the Forefront of Drug Development in China
10.1.3 Biologics in China – Biosimilars to Lead the Way
10.1.4 The Anhui Model – Discussion
10.1.5 IP Protection in China is Robust
10.1.6 Consolidating the Fragmented Chinese Market
10.1.7 Access to the Chinese Pharmaceutical Market
10.1.8 The Unsustainable Anhui Model Leads to a Drop in Quality
10.1.9 IP Protection in China is Robust
10.1.10 Consolidating the Fragmented Chinese Market
10.1.11 Access to the Chinese Pharmaceutical Market
10.2 Interview with Benjamin Shobert, Teleos Consulting
10.2.1 Drug Revenues and the Anhui Model
10.2.2 ‘Heaven is High, and the Emperor is Far Away’: Government Policy in Theory and its Implementation in Practice
10.2.3 IP and Technology Transfer in China
10.2.4 Big Pharma Strategies in China
10.2.5 One Country, Two Healthcare Systems?
10.2.6 Innovation in China
10.2.7 The Big Picture in the Next Ten Years
10.3 Interview with Justin Chakma, Thomas, McNerney & Partners
10.3.1 Differences Between Innovation in China and in Other Emerging Markets
10.3.2 Funding Advantages for Chinese Biotech
10.3.3 Investment Targets for Chinese Venture Capital
10.3.4 Dominance of Oncology in Chinese R&D
10.3.5 Restraints on Innovation in China
10.3.6 Important Coming Trends in Chinese R&D and Venture Capital Funding
10.4 Interview with Julie Li, Strategy Manger, China Resources Double-Crane Pharmaceuticals, China
10.4.1 Multinational Dominate Drug Discover in China
10.4.2 Cancer and Chronic Disease are Critical
10.4.3 The Impact of Control on Antibacterial Drug Prescriptions
10.4.4 New GMP Regulation Will lead to Consolidation of Drug Manufacturers

11. Conclusions
11.1 China: The Crucial Growth Market for Pharmaceuticals, 2014-2024
11.2 The Leading Therapeutic Areas Within the Chinese Pharmaceutical Market
11.3 Top Ten Pharmaceutical Companies Dominated by Domestic Firms
11.4 Healthcare Reforms Will Put Greater Emphasis on Pharmacy Sales
11.5 International Pharmaceutical Companies Use China’s Outsourcing Capacity
11.6 Generic Drugs and TCM Remain Crucial to the Chinese Pharmaceutical Market
11.7 China: The Greatest Challenge and Opportunity for the Pharmaceutical Industry



List of Tables
Table 1.1 Chinese Pharmaceutical Market Forecast by Therapy Area: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 1.2 Chinese Pharmaceutical Market Forecast by Therapy Area: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 1.3 Foreign Currency Exchange Rates Utilised: Average Exchange Rate to $US, 2013
Table 2.1 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), 2013
Table 2.2 Regional Pharma Markets of the World ($bn), Market Shares (%), 2013
Table 2.3 Chinese Pharmaceutical Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 2.4 Chinese Pharmaceutical Distribution Market by Sales Channel: Market Size ($bn), Market Share (%), 2013
Table 2.5 Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), Market Share (%), 2013
Table 2.6 Chinese Pharmaceutical Manufacturing Output Market by Product Class: Output ($bn), Market Share (%), 2013
Table 2.7 Chinese Pharmaceutical Contract Research Market by Area: Market Size ($bn), Market Share (%), 2013
Table 2.8 Top 30 Domestic Chinese Pharmaceutical Producers: Revenue ($bn), Market Share (%), 2013
Table 2.9 Top 10 Multinational Pharmaceutical Companies in Domestic Chinese Market: Revenue ($bn), Market Share (%), 2013
Table 2.10 Some Chinese Activities of Top 25 Global Pharmaceutical Companies, 2013
Table 2.11 Some Chinese Activities of Top 25 Global Pharmaceutical Companies, 2013 (Continued)
Table 2.12 Healthcare Reform in China, 2009-2015
Table 2.13 Selected High-Profile New Entrants to China’s Essential Drugs List, 2012
Table 3.1 Prominent Diseases in China: Prevalences (000s), CAGR (%), 2012, 2015, 2020 and 2025
Table 3.2 Prominent Diseases in China: Incidences (000s), CAGR (%),2012, 2015, 2020 and 2025
Table 3.3 Top 15 Broad Causes of Death in China: Deaths (000s), Proportion of Overall Deaths (%), 2012
Table 3.4 Top 25 Specific Causes of Death in China: Deaths (000s), Proportion of Overall Deaths, 2012
Table 3.5 Forecast Broad Causes of Deaths in China: Number of Deaths (000s), CAGR (%), 2015 and 2025
Table 3.6 Forecast Top 25 Specific Causes of Deaths in China: Number of Deaths (000s), CAGR (%), 2015 and 2025
Table 4.1 Forecast Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2018
Table 4.2 Forecast Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2024
Table 4.3 Forecast Chinese Pharmaceutical Sales Through Hospitals: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2024
Table 4.4 Forecast Chinese Pharmaceutical Sales Through Retail Pharmacies: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2024
Table 4.5 Forecast Chinese OTC Drug Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2024
Table 4.6 Selected Chinese OTC Drug Manufacturers: OTC Drug Revenues ($m), Market Shares (%), 2013
Table 4.7 Forecast Chinese Pharmaceutical Sales Through Other Channels: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2024
Table 4.8 Forecast Chinese Pharmaceutical Contract Sales Spending: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2024
Table 5.1 Forecast Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2018
Table 5.2 Forecast Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2024
Table 5.3 Forecast Chinese Small-Molecule Pharmaceutical Market: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2024
Table 5.4 Forecast Chinese Small-Molecule Pharmaceutical Market by Segment: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2018
Table 5.5 Forecast Chinese Small-Molecule Pharmaceutical Market by Segment: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2024
Table 5.6 Forecast Chinese Traditional Medicine Market: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2024
Table 5.7 Selected Traditional Chinese Medicine Manufacturers and Their Activities, 2014
Table 5.8 Forecast Chinese Biological Medicines Markets: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2018
Table 5.9 Forecast Chinese Biological Medicines Markets: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2024
Table 5.10 Chinese Biosimilar Manufacturers and Their Product Lines, 2013
Table 6.1 Forecast Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2018
Table 6.2 Forecast Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 6.3 Forecast Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2013-2024
Table 6.4 Chinese Infectious Disease Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.5 Chinese Antibacterial Drug Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.6 Chinese Antibacterial Drug Market by Drug Class: Market Size ($bn), Market Share (%), 2013
Table 6.7 Selected Domestic Chinese Antibacterial Drug Manufacturers and Their Activities, 2014
Table 6.8 Chinese Vaccine Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.9 Chinese Antiviral Drug Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.10 Chinese Cardiovascular Disease Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.11 Chinese Hypertension Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.12 Chinese Hypertension Market by Drug Class: Market Size ($bn), Market Share (%), 2013
Table 6.13 Chinese Hypertension Market by Company Revenue: Revenue ($bn), Market Share (%), 2013
Table 6.14 Chinese Dyslipidaemia Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.15 Selected Domestic Chinese Cardiovascular Drug Manufacturers and Their Activities, 2014
Table 6.16 Chinese Anticancer Drug Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.17 Incidence of Types of Cancer in China: Incidence (000s), CAGR (%), 2012, 2015, 2020 and 2025
Table 6.18 Cancer Treatments on the Chinese Essential Drugs List, 2012 Edition
Table 6.19 Selected Domestic Chinese Anticancer Drug Manufacturers and Their Activities, 2014
Table 6.20 Chinese Diabetes Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.21 Selected Domestic Chinese Anti-Diabetic Drug Manufacturers and Their Activities, 2014
Table 6.22 Chinese CNS Diseases Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.23 Chinese Antidepressant Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.24 Chinese Antidepressant Drug Market by Product Class: Sales ($bn), Market Share (%), 2013
Table 6.25 Chinese Antipsychotic Drug Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.26 Chinese Antipsychotics Market by Product Class: Market Share by Sales Volume (%), 2013
Table 6.27 Chinese Respiratory Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.28 Chinese COPD Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.29 Chinese Asthma Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.30 Chinese Respiratory Drug Market by Product Class: Sales ($bn), Market Share (%), 2013
Table 6.31 Chinese Autoimmune and Inflammatory Diseases Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 6.32 Forecast Other Disease Areas in The Chinese Market: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2014-2024
Table 7.1 Chinese Pharmaceutical Contract Manufacturing Market Forecast: Market Size ($bn), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2014-2024
Table 7.2 Chinese Pharmaceutical Manufacturing Output by Product Class: Output ($bn), Manufacturing Market Share (%), 2011-2013
Table 7.3 Forecast Chinese Pharmaceutical Manufacturing Output by Product Class: Output ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2014-2018
Table 7.4 Forecast Chinese Pharmaceutical Manufacturing Output by Product Class: Output ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2018-2024
Table 7.5 Forecast Chinese Traditional Medicine Manufacturing Output: Output ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2014-2024
Table 7.6 TCM Exports by Country: Value ($bn), Export Share (%), 2013
Table 7.7 Forecast Chinese Pharmaceutical Formulation Manufacturing Output: Output ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2014-2024
Table 7.8 Forecast Chinese Chemical API Manufacturing Output: Output ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2014-2024
Table 7.9 Forecast Chinese Biological & Biochemical Drug Manufacturing Output: Output ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2014-2024
Table 7.10 Forecast Chinese Medical Device Manufacturing Output: Output ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2014-2024
Table 8.1 Forecast Chinese Contract Research Outsourcing Market by Activity: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2018
Table 8.2 Forecast Chinese Contract Research Outsourcing Market by Activity: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2024
Table 8.3 Number of Clinical Trials Registered In China by Phase, 2005-2013
Table 8.4 Selected Domestic Contract Research Organisations and Their Activities, 2013
Table 8.5 Selected Domestic Chinese Companies With Innovative Pharmaceutical Pipelines, 2013
Table 11.1 Summary of Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), CAGR (%), 2013, 2018, 2024
Table 11.2 Summary of Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), Market Share (%), CAGR (%), 2013, 2018, 2024
Table 11.3 Top Ten Pharmaceutical Companies by Chinese Drug Sales: Revenue ($bn), Market Share (%), 2013

【レポートのキーワード】

中国、製薬、医薬品、販売チャネル、製造

★調査レポート[中国の製薬市場予測と展望(2014-2024)] ( CHINESE PHARMACEUTICAL MARKET: FORECASTS AND OUTLOOKS 2014-2024 / VISG409046) 販売に関する免責事項
[中国の製薬市場予測と展望(2014-2024)] ( CHINESE PHARMACEUTICAL MARKET: FORECASTS AND OUTLOOKS 2014-2024 / VISG409046) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆